Prolonged duration of response in lenvatinib responders with thyroid cancer (Russian translation)
| العنوان: | Prolonged duration of response in lenvatinib responders with thyroid cancer (Russian translation) |
|---|---|
| المؤلفون: | Matthew Guo, Andrew G. Gianoukakis, N. Batty, Corina E. Dutcus, Mahadi Ali Baig |
| المصدر: | Opuholi Golovy i Šei, Vol 8, Iss 3, Pp 53-60 (2018) |
| بيانات النشر: | ABV-press, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | Cancer Research, medicine.medical_specialty, radioiodine-refractory differentiated thyroid carcinoma, Phases of clinical research, lenvatinib, Placebo, Gastroenterology, chemistry.chemical_compound, select, Internal medicine, Medicine, Pharmacology (medical), Radiology, Nuclear Medicine and imaging, In patient, Objective response, Thyroid cancer, duration of response, RC254-282, business.industry, Hazard ratio, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, Confidence interval, Oncology, Otorhinolaryngology, chemistry, Surgery, business, Lenvatinib |
| الوصف: | We present an updated analysis of lenvatinib in radioiodine-refractory differentiated thyroid cancer (RR-DTC) with new duration of response (DOR) data unavailable for the primary analysis. In this randomized, double-blind, multicenter, placebo-controlled phase 3 study, patients ≥18 years old with measurable, pathologically confirmed RR-DTC with independent radiologic confirmation of disease progression within the previous 13 months were randomized 2:1 to oral lenvatinib 24 mg/day or placebo. The main outcome measures for this analysis are DOR and progression-free survival (PFS). The median DOR for all lenvatinib responders (patients with complete or partial responses; objective response rate: 60.2 %; 95 % confidence interval (CI) 54.2–66.1) was 30.0 months (95 % CI 18.4–36.7) and was generally similar across subgroups. DOR was shorter in patients with greater disease burden and with brain and liver metastases. Updated median PFS was longer in the overall lenvatinib group vs placebo (19.4 vs 3.7 months; hazard ratio (HR) 0.24; 99 % CI 0.17–0.35; nominal P |
| اللغة: | Russian |
| تدمد: | 2411-4634 2222-1468 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a3ba1578abc7de57b5aba8887762bab https://ogsh.abvpress.ru/jour/article/view/361 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....1a3ba1578abc7de57b5aba8887762bab |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 24114634 22221468 |
|---|